Around 30% of colorectal cancer patients have some family history or hereditary genetic risk of the disease. The other 70% of patients don’t. ¹ ²
Despite these stats, there is still a focus on family history risk.¹
How will you help the 70% of patients with actionable risk of colorectal cancer who also have no family history?
Learn more about the geneType™ colorectal cancer test which goes beyond hereditary risk, looking at genetic and clinical risk factors to give you a comprehensive risk prediction so that you can take preventative steps to improve health and mitigate your risk.
geneType™ identifies asymptomatic, healthy adults who may be at higher risk of colorectal cancer.
Colorectal cancer incidence is on the rise in adults under 50.2,3
Screening guidelines have tried to address this issue by lowering national screening recommendations to age 45 years.²
Patients are already stratified by family history, race/ethnicity, inflammatory bowel disease and obesity to assist with tailoring screening options.²
Take risk stratification one step further by understanding your patient’s “baseline” risk with geneType.
*If your patient shows symptoms associated with CRC, do not use a risk assessment like geneType.
What action can you take?
geneType™ for Colorectal Cancer is appropriate for:
Register as a provider; our team will provide clinical education and other resources as needed.
We will send kits to your clinic to have on hand.
Discuss geneType™ with your patient.
Would geneType™ help them qualify for additional risk reduction strategies?
Complete the Test Requisition form, collect a saliva sample from the patient with the collection kit provided and return both to Rhythm.
You will have the option to use a paper requisition, or a secure, compliant portal to complete the ordering process.
Leave the rest to us.
We will notify you when your patient’s results are ready.
You will have the option to request a consult with a genetic counsellor, whether to review your patient’s results and/or to follow-up with your patient, as needed.
geneType™ reports are structured to make the results easy to interpret and communicate to a patient.
The geneType™ for Colorectal Cancer report includes:
If your question is not shown here, please Contact us directly.
Yes.
Most people diagnosed with CRC do not have a first degree relative affected by colorectal cancer.1,2
geneType™ for Colorectal Cancer incorporates polygenic risk to deliver a baseline understanding of your patient’s risk of CRC.
While geneType™ is not a replacement for current FOBT recommendations:
No.
geneType™ for Colorectal Cancer is a DNA-based risk assessment collected with a saliva tube.
“DNA markers” is a simple term we use to describe small differences in DNA between individuals.
geneType™ for Colorectal Cancer looks at DNA markers that have been scientifically proven to be associated with colorectal cancer through genome wide association studies and then cross-validated in our own lab.
A polygenic risk score is calculated by combining the effects of multiple DNA markers. While one or two DNA markers don’t have a strong influence on risk, many markers together can have a large impact. Your patient’s polygenic risk score adds up the effects of many DNA markers.
This test is not generally covered by insurance. Your ordering healthcare provider will discuss the cost of the test with you. A credit card authorization form will be included in the test kit that lists the payment options. You may use your FSA/HSA to pay for the test.
*Patient eligibility dependent on personal medical history, age and sex
The Multi-Risk suite of tests is for adults 40-85 years of age. At maximum, a woman would be eligible for eight diseases in the panel; a man would be eligible for seven. Starting at age 30, a patient may qualify for geneType’s™ cancer risk assessments only.
The first step is to trial geneType™ at your practice.
Accredited For Compliance With NPAAC Standards And ISO 15189
